EpiHeart is a young medical device company dedicated to enable surgical administration of novel cellular and gene therapies. Our first focus is Cardiac Micrograft Therapy, a novel autologous cellular therapy administered during CABG surgery to treat ischemic cardiac scars and heart failure.
EpiHeart is dedicated to enable new treatments that improve long term survival and quality of life of cardiac patients. Our initial focus is in Cardiac Micrograft Therapy(TM). During Cardiac Artery Bypass Grafting (CABG) surgery patient's own cardiac tissue is processed into micrografts, cleaned and transplanted back to support cardiac tissue regeneration. The pre-clinical and clinical results indicate positive effects on ventricular wall structure and scar size - critical factors contributing to heart failure.
EpiHeart is a University spin-off company leveraging over 10 years of dedicated research conducted on three continents. Our home is Helsinki, Finland, where we continue collaboration with University of Helsinki, Helsinki University Hospital "HUS" and Aalto University.
EpiHeart is open for collaboration. We foresee collaboration possibilites in following areas:
Feel free to request further information on our science, clinical trial program and more.